Source link : https://www.newshealth.biz/health-news/less-frequent-cisplatin-superior-in-head-neck-cancer/
TOPLINE: A long-term follow-up analysis revealed that cisplatin administered at 100 mg/m2 once every 3 weeks provides superior locoregional control and may offer longer overall survival than 30 mg/m2 cisplatin once a week in patients with locally advanced head and neck cancer. Aside from hearing dysfunction, adverse events were similar between the two groups. METHODOLOGY: […]
Author : News Health
Publish date : 2024-08-13 11:50:06
Copyright for syndicated content belongs to the linked Source.
Categories